{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T18:26:05Z","timestamp":1781807165872,"version":"3.54.5"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-24863-2","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T14:05:48Z","timestamp":1765548348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma associated fibroblasts"],"prefix":"10.1038","volume":"15","author":[{"given":"Bel\u00e9n","family":"Toledo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aitor","family":"Gonz\u00e1lez-Titos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Hern\u00e1ndez-Camarero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"L\u00f3pez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Gri\u00f1\u00e1n-Lis\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Giovannetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Antonio","family":"Marchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"Per\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"9","key":"24863_CR1","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho, W. J., Jaffee, E. M. & Zheng, L. The tumor microenvironment in pancreatic cancer \u2014 clinical challenges and opportunities. Nat. Reviews Clin. Oncol. 17 (9), 527\u2013540. https:\/\/doi.org\/10.1038\/s41571-020-0363-5 (2020).","journal-title":"Nat. Reviews Clin. Oncol."},{"key":"24863_CR2","doi-asserted-by":"publisher","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E., Jemal, A. & Cancer statistics CA: A Cancer Journal for Clinicians. 2022; 72(1):7\u201333. (2022). https:\/\/doi.org\/10.3322\/caac.21708","DOI":"10.3322\/caac.21708"},{"issue":"3","key":"24863_CR3","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1053\/j.gastro.2021.11.021","volume":"162","author":"A Chhoda","year":"2022","unstructured":"Chhoda, A. et al. Late-stage pancreatic cancer detected during high-risk individual surveillance: A systematic review and meta-analysis. Gastroenterology 162 (3), 786\u2013798. https:\/\/doi.org\/10.1053\/j.gastro.2021.11.021 (2022).","journal-title":"Gastroenterology"},{"issue":"2","key":"24863_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4251\/wjgo.v12.i2.173","volume":"12","author":"P Sarantis","year":"2020","unstructured":"Sarantis, P., Koustas, E., Papadimitropoulou, A., Papavassiliou, A. G. & Karamouzis, M. V. Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy. World J. Gastrointest. Oncol. 12 (2), 173\u2013181. https:\/\/doi.org\/10.4251\/wjgo.v12.i2.173 (2020).","journal-title":"World J. Gastrointest. Oncol."},{"issue":"8","key":"24863_CR5","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3390\/cancers11081136","volume":"11","author":"E Rodriguez-Aznar","year":"2019","unstructured":"Rodriguez-Aznar, E., Wiesm\u00fcller, L., Sainz, B. & Hermann, P. C. EMT and stemness\u2014key players in pancreatic cancer stem cells. Cancers 11 (8), 1136. https:\/\/doi.org\/10.3390\/cancers11081136 (2019).","journal-title":"Cancers"},{"issue":"8","key":"24863_CR6","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.cd-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada, E. et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 9 (8), 1102\u20131123. https:\/\/doi.org\/10.1158\/2159-8290.cd-19-0094 (2019).","journal-title":"Cancer Discov."},{"key":"24863_CR7","doi-asserted-by":"publisher","unstructured":"Bulle, A. & Lim, K-H. Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer. Signal. Transduct. Target. Therapy. 5 (1). https:\/\/doi.org\/10.1038\/s41392-020-00341-1 (2020).","DOI":"10.1038\/s41392-020-00341-1"},{"issue":"2","key":"24863_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2159-8290.cd-18-0710","volume":"9","author":"G Biffi","year":"2019","unstructured":"Biffi, G. et al. Il1-induced JAK\/STAT signaling is antagonized by TGF\u0392 to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 9 (2), 282\u2013301. https:\/\/doi.org\/10.1158\/2159-8290.cd-18-0710 (2019).","journal-title":"Cancer Discov."},{"issue":"1","key":"24863_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1152\/physrev.00048.2019","volume":"101","author":"G Biffi","year":"2021","unstructured":"Biffi, G. & Tuveson, D. A. Diversity and biology of cancer-associated fibroblasts. Physiol. Rev. 101 (1), 147\u2013176. https:\/\/doi.org\/10.1152\/physrev.00048.2019 (2021).","journal-title":"Physiol. Rev."},{"issue":"24","key":"24863_CR10","doi-asserted-by":"publisher","first-page":"15576","DOI":"10.3390\/ijms232415576","volume":"23","author":"B Toledo","year":"2022","unstructured":"Toledo, B., Picon-Ruiz, M., Marchal, J. A. & Per\u00e1n, M. Dual role of fibroblasts educated by tumor in cancer behavior and therapeutic perspectives. Int. J. Mol. Sci. 23 (24), 15576. https:\/\/doi.org\/10.3390\/ijms232415576 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"24863_CR11","doi-asserted-by":"publisher","unstructured":"Chakkera, M., Foote, J. B., Farran, B. & Nagaraju, G. P. Breaking the stromal barrier in pancreatic cancer: advances and challenges. Biochimica et biophysica acta (BBA) - Reviews on cancer. ;1879(1):189065. (2024). https:\/\/doi.org\/10.1016\/j.bbcan.2023.189065","DOI":"10.1016\/j.bbcan.2023.189065"},{"issue":"15","key":"24863_CR12","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.3390\/cancers14153737","volume":"14","author":"S Cannone","year":"2022","unstructured":"Cannone, S. et al. Cancer associated fibroblast (CAF) regulation of PDAC parenchymal (CPC) and CSC phenotypes is modulated by ECM composition. Cancers 14 (15), 3737. https:\/\/doi.org\/10.3390\/cancers14153737 (2022).","journal-title":"Cancers"},{"issue":"7","key":"24863_CR13","doi-asserted-by":"publisher","first-page":"101107","DOI":"10.1016\/j.tranon.2021.101107","volume":"14","author":"X Liu","year":"2021","unstructured":"Liu, X. et al. 3D heterospecies spheroids of pancreatic stroma and cancer cells demonstrate key phenotypes of pancreatic ductal adenocarcinoma. Translational Oncol. 14 (7), 101107. https:\/\/doi.org\/10.1016\/j.tranon.2021.101107 (2021).","journal-title":"Translational Oncol."},{"key":"24863_CR14","doi-asserted-by":"publisher","unstructured":"G\u00f6tze, J. et al. Tumor-stroma interaction in PDAC as a new approach for liquid biopsy and its potential clinical implications. Front. Cell. Dev. Biology. 10 https:\/\/doi.org\/10.3389\/fcell.2022.918795 (2022).","DOI":"10.3389\/fcell.2022.918795"},{"key":"24863_CR15","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","volume":"55","author":"D Yang","year":"2023","unstructured":"Yang, D. et al. Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp. Mol. Med. 55, 1322\u20131332. https:\/\/doi.org\/10.1038\/s12276-023-01013-0 (2023).","journal-title":"Exp. Mol. Med."},{"key":"24863_CR16","doi-asserted-by":"publisher","unstructured":"Thomas, D. & Radhakrishnan, P. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol. Cancer. 18 (1). https:\/\/doi.org\/10.1186\/s12943-018-0927-5 (2019).","DOI":"10.1186\/s12943-018-0927-5"},{"issue":"5","key":"24863_CR17","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nrc1877","volume":"6","author":"R Kalluri","year":"2006","unstructured":"Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer. 6 (5), 392\u2013401. https:\/\/doi.org\/10.1038\/nrc1877 (2006).","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"24863_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.gde.2009.01.003","volume":"19","author":"A \u00d6stman","year":"2009","unstructured":"\u00d6stman, A. & Augsten, M. Cancer-associated fibroblasts and tumor growth \u2013 bystanders turning into key players. Curr. Opin. Genet. Dev. 19 (1), 67\u201373. https:\/\/doi.org\/10.1016\/j.gde.2009.01.003 (2009).","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"3","key":"24863_CR19","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai, E. et al. A framework for advancing our Understanding of cancer-associated fibroblasts. Nat. Rev. Cancer. 20 (3), 174\u2013186. https:\/\/doi.org\/10.1038\/s41568-019-0238-1 (2020).","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"24863_CR20","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.3390\/ijms24054487","volume":"24","author":"B Toledo","year":"2023","unstructured":"Toledo, B., Gonz\u00e1lez-Titos, A., Hern\u00e1ndez-Camarero, P. & Per\u00e1n, M. A brief review on chemoresistance; targeting cancer stem cells as an alternative approach. Int. J. Mol. Sci. 24 (5), 4487. https:\/\/doi.org\/10.3390\/ijms24054487 (2023).","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"24863_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41571-019-0281-6","volume":"17","author":"C Nevala-Plagemann","year":"2019","unstructured":"Nevala-Plagemann, C., Hidalgo, M. & Garrido-Laguna, I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat. Reviews Clin. Oncol. 17 (2), 108\u2013123. https:\/\/doi.org\/10.1038\/s41571-019-0281-6 (2019).","journal-title":"Nat. Reviews Clin. Oncol."},{"key":"24863_CR22","doi-asserted-by":"publisher","unstructured":"Hu, C. et al. CIRCFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF\/stat3 axis. Mol. Cancer. 21 (1). https:\/\/doi.org\/10.1186\/s12943-022-01501-3 (2022).","DOI":"10.1186\/s12943-022-01501-3"},{"issue":"22","key":"24863_CR23","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.1158\/0008-5472.CAN-19-0960","volume":"79","author":"S Dalin","year":"2019","unstructured":"Dalin, S. et al. Deoxycytidine release from pancreatic stellate cells promotes gemcitabine resistance. Cancer Res. 79 (22), 5723\u20135733. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0960 (2019).","journal-title":"Cancer Res."},{"issue":"12","key":"24863_CR24","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41423-022-00930-w","volume":"19","author":"HJ Kim","year":"2022","unstructured":"Kim, H. J. et al. Reprogramming of cancer-associated fibroblasts by apoptotic cancer cells inhibits lung metastasis via notch1-WISP-1 signaling. Cell Mol. Immunol. 19 (12), 1373\u20131391. https:\/\/doi.org\/10.1038\/s41423-022-00930-w (2022).","journal-title":"Cell Mol. Immunol."},{"key":"24863_CR25","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.3390\/cancers13051172","volume":"13","author":"IH Ham","year":"2021","unstructured":"Ham, I. H., Lee, D. & Hur, H. Cancer-Associated Fibroblast-Induced resistance to chemotherapy and radiotherapy in Gastrointestinal cancers. Cancers (Basel). 13, 1172. https:\/\/doi.org\/10.3390\/cancers13051172 (2021).","journal-title":"Cancers (Basel)"},{"issue":"16","key":"24863_CR26","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.3390\/cancers14163906","volume":"14","author":"RA Glabman","year":"2022","unstructured":"Glabman, R. A., Choyke, P. L. & Sato, N. Cancer-associated fibroblasts: tumorigenicity and targeting for cancer therapy. Cancers 14 (16), 3906. https:\/\/doi.org\/10.3390\/cancers14163906 (2022).","journal-title":"Cancers"},{"key":"24863_CR27","doi-asserted-by":"publisher","unstructured":"de Sostoa, J. et al. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager. J. Immunother. Cancer. 7 (1). https:\/\/doi.org\/10.1186\/s40425-019-0505-4 (2019).","DOI":"10.1186\/s40425-019-0505-4"},{"issue":"12","key":"24863_CR28","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1080\/14712598.2021.1922666","volume":"21","author":"A Gonz\u00e1lez-Titos","year":"2021","unstructured":"Gonz\u00e1lez-Titos, A. et al. Trypsinogen and chymotrypsinogen: potent anti-tumor agents. Expert Opin. Biol. Ther. 21 (12), 1609\u20131621. https:\/\/doi.org\/10.1080\/14712598.2021.1922666 (2021).","journal-title":"Expert Opin. Biol. Ther."},{"key":"24863_CR29","doi-asserted-by":"publisher","unstructured":"Per\u00e1n, M. et al. A formulation of pancreatic pro-enzymes provides potent anti-tumor efficacy: A pilot study focused on pancreatic and ovarian cancer. Sci. Rep. 7 (1). https:\/\/doi.org\/10.1038\/s41598-017-14571-x (2017).","DOI":"10.1038\/s41598-017-14571-x"},{"issue":"6","key":"24863_CR30","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris, H. A. 3rd. et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15(6), 2403\u20132413. https:\/\/doi.org\/10.1200\/JCO.1997.15.6.2403 (1997) (PMID: 9196156).","journal-title":"J. Clin. Oncol."},{"key":"24863_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2024.2319340","author":"B Toledo","year":"2024","unstructured":"Toledo, B. et al. Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical Pharmacology perspectives. Expert Rev. Clin. Pharmacol. https:\/\/doi.org\/10.1080\/17512433.2024.2319340 (2024).","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"1","key":"24863_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00280-007-0473-0","volume":"61","author":"RL Fine","year":"2008","unstructured":"Fine, R. L. et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother. Pharmacol. 61 (1), 167\u2013175 (2008).","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"18","key":"24863_CR33","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl. J. Med. 369 (18), 1691\u20131703 (2013).","journal-title":"N Engl. J. Med."},{"issue":"4","key":"24863_CR34","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2165\/00003495-200059040-00004","volume":"59","author":"J Leipner","year":"2000","unstructured":"Leipner, J. & Saller, R. Systemic enzyme therapy in oncology. Drugs 59 (4), 769\u2013780. https:\/\/doi.org\/10.2165\/00003495-200059040-00004 (2000).","journal-title":"Drugs"},{"key":"24863_CR35","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.canlet.2018.04.042","volume":"429","author":"G Jim\u00e9nez","year":"2018","unstructured":"Jim\u00e9nez, G. et al. Mesenchymal stem cell\u2019s secretome promotes selective enrichment of cancer stem-like cells with specific cytogenetic profile. Cancer Lett. 429, 78\u201388. https:\/\/doi.org\/10.1016\/j.canlet.2018.04.042 (2018).","journal-title":"Cancer Lett."},{"issue":"5","key":"24863_CR36","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.7150\/ijbs.68484","volume":"18","author":"S Peng","year":"2022","unstructured":"Peng, S. et al. Metabolomics reveals that CAF-derived lipids promote colorectal cancer peritoneal metastasis by enhancing membrane fluidity. Int. J. Biol. Sci. 18 (5), 1912\u20131932. https:\/\/doi.org\/10.7150\/ijbs.68484 (2022).","journal-title":"Int. J. Biol. Sci."},{"key":"24863_CR37","doi-asserted-by":"publisher","unstructured":"Hern\u00e1ndez-Camarero, P. et al. Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic cancer stem cell subpopulation and impairs tumor engrafting. Sci. Rep. 9 (1). https:\/\/doi.org\/10.1038\/s41598-019-47837-7 (2019).","DOI":"10.1038\/s41598-019-47837-7"},{"issue":"4","key":"24863_CR38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s13402-013-0134-8","volume":"36","author":"M Per\u00e1n","year":"2013","unstructured":"Per\u00e1n, M., Marchal, J. A., Garc\u00eda, M. A., Kenyon, J. & Tosh, D. Vitro treatment of carcinoma cell lines with pancreatic (pro)enzymes suppresses the EMT programme and promotes cell differentiation. Cell. Oncol. 36 (4), 289\u2013301. https:\/\/doi.org\/10.1007\/s13402-013-0134-8 (2013).","journal-title":"Cell. Oncol."},{"issue":"19","key":"24863_CR39","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1038\/s41388-022-02288-9","volume":"41","author":"T Iida","year":"2022","unstructured":"Iida, T. et al. Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeutics. Oncogene 41 (19), 2764\u20132777. https:\/\/doi.org\/10.1038\/s41388-022-02288-9 (2022).","journal-title":"Oncogene"},{"key":"24863_CR40","doi-asserted-by":"publisher","unstructured":"Ligorio, M. et al. Stromal microenvironment shapes the intratumoral architecture of pancreatic cancer. Cell 178 (1). https:\/\/doi.org\/10.1016\/j.cell.2019.05.012 (2019).","DOI":"10.1016\/j.cell.2019.05.012"},{"issue":"10","key":"24863_CR41","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41416-018-0246-z","volume":"119","author":"D Melisi","year":"2018","unstructured":"Melisi, D. et al. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. Br. J. Cancer. 119 (10), 1208\u20131214. https:\/\/doi.org\/10.1038\/s41416-018-0246-z (2018).","journal-title":"Br. J. Cancer"},{"issue":"7","key":"24863_CR42","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/odi.13306","volume":"26","author":"P Ba","year":"2020","unstructured":"Ba, P. et al. Curcumin suppresses the proliferation and tumorigenicity of cal27 by modulating cancer-associated fibroblasts of TSCC. Oral Dis. 26 (7), 1375\u20131383. https:\/\/doi.org\/10.1111\/odi.13306 (2020).","journal-title":"Oral Dis."},{"issue":"6","key":"24863_CR43","doi-asserted-by":"publisher","first-page":"975","DOI":"10.21037\/tlcr-22-10","volume":"11","author":"M Sugai","year":"2022","unstructured":"Sugai, M. et al. Correlation of tumor microenvironment-related markers with clinical outcomes in patients with squamous cell carcinoma of the lung. Translational Lung Cancer Res. 11 (6), 975\u2013990. https:\/\/doi.org\/10.21037\/tlcr-22-10 (2022).","journal-title":"Translational Lung Cancer Res."},{"issue":"3","key":"24863_CR44","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00259-021-05554-2","volume":"49","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. Fibroblast activation protein targeted therapy using [177lu]fapi-46 compared with [225AC]FAPI-46 in a pancreatic cancer model. Eur. J. Nucl. Med. Mol. Imaging. 49(3), 871\u2013880. https:\/\/doi.org\/10.1007\/s00259-021-05554-2 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"issue":"7","key":"24863_CR45","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1007\/s12094-022-02777-z","volume":"24","author":"X-K Cao","year":"2022","unstructured":"Cao, X-K., Xie, B., Shao, Y. & Lin, J. Cytokine-driven positive feedback loop organizes fibroblast transformation and facilitates gastric cancer progression. Clin. Transl. Oncol. 24 (7), 1354\u20131364. https:\/\/doi.org\/10.1007\/s12094-022-02777-z (2022).","journal-title":"Clin. Transl. Oncol."},{"key":"24863_CR46","doi-asserted-by":"publisher","unstructured":"Hern\u00e1ndez-Camarero, P., L\u00f3pez-Ruiz, E., Marchal, J. A., Per\u00e1n, M. & Cancer A mirrored room between tumor bulk and tumor microenvironment. J. Experimental Clin. Cancer Res. 40 (1). https:\/\/doi.org\/10.1186\/s13046-021-02022-5 (2021).","DOI":"10.1186\/s13046-021-02022-5"},{"issue":"5","key":"24863_CR47","doi-asserted-by":"publisher","first-page":"262","DOI":"10.21037\/atm-22-407","volume":"10","author":"B Hu","year":"2022","unstructured":"Hu, B. et al. Subpopulations of cancer-associated fibroblasts link the prognosis and metabolic features of pancreatic ductal adenocarcinoma. Annals Translational Med. 10 (5), 262\u2013262. https:\/\/doi.org\/10.21037\/atm-22-407 (2022).","journal-title":"Annals Translational Med."},{"issue":"14","key":"24863_CR48","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.3390\/cancers14143486","volume":"14","author":"D Kim","year":"2022","unstructured":"Kim, D. et al. Identification and characterization of cancer-associated fibroblast subpopulations in lung adenocarcinoma. Cancers 14 (14), 3486. https:\/\/doi.org\/10.3390\/cancers14143486 (2022).","journal-title":"Cancers"},{"issue":"10","key":"24863_CR49","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41388-021-02171-z","volume":"41","author":"B Chiavarina","year":"2022","unstructured":"Chiavarina, B. et al. Fibroblast-derived prolargin is a tumor suppressor in hepatocellular carcinoma. Oncogene 41 (10), 1410\u20131420. https:\/\/doi.org\/10.1038\/s41388-021-02171-z (2022).","journal-title":"Oncogene"},{"issue":"6","key":"24863_CR50","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1158\/2159-8290.cd-20-1484","volume":"12","author":"KM McAndrews","year":"2022","unstructured":"McAndrews, K. M. et al. Identification of functional heterogeneity of carcinoma-associated fibroblasts with distinct IL6-mediated therapy resistance in pancreatic cancer. Cancer Discov. 12 (6), 1580\u20131597. https:\/\/doi.org\/10.1158\/2159-8290.cd-20-1484 (2022).","journal-title":"Cancer Discov."},{"issue":"8","key":"24863_CR51","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1136\/gutjnl-2022-329371","volume":"72","author":"E Karamitopoulou","year":"2023","unstructured":"Karamitopoulou, E. et al. Spatially restricted tumor-associated and host-associated immune drivers correlate with the recurrence sites of pancreatic cancer. Gut 72 (8), 1523\u20131533. https:\/\/doi.org\/10.1136\/gutjnl-2022-329371 (2023).","journal-title":"Gut"},{"issue":"3","key":"24863_CR52","doi-asserted-by":"publisher","first-page":"464","DOI":"10.7150\/jca.80115","volume":"14","author":"MR Akanda","year":"2023","unstructured":"Akanda, M. R. et al. Different expression and clinical implications of cancer-associated fibroblast (CAF) markers in brain metastases. J. Cancer. 14 (3), 464\u2013479. https:\/\/doi.org\/10.7150\/jca.80115 (2023).","journal-title":"J. Cancer"},{"issue":"20","key":"24863_CR53","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1158\/0008-5472.can-19-0454","volume":"79","author":"Y Mizutani","year":"2019","unstructured":"Mizutani, Y. et al. Meflin-positive cancer-associated fibroblasts inhibit pancreatic carcinogenesis. Cancer Res. 79 (20), 5367\u20135381. https:\/\/doi.org\/10.1158\/0008-5472.can-19-0454 (2019).","journal-title":"Cancer Res."},{"key":"24863_CR54","doi-asserted-by":"publisher","unstructured":"Miyai, Y. et al. Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint Blockade. Life Sci. Alliance. 5 (6). https:\/\/doi.org\/10.26508\/lsa.202101230 (2022).","DOI":"10.26508\/lsa.202101230"},{"key":"24863_CR55","doi-asserted-by":"publisher","unstructured":"Yoon, H. et al. TGF-\u03b21-mediated transition of resident fibroblasts to cancer-associated fibroblasts promotes cancer metastasis in Gastrointestinal stromal tumor. Oncogenesis 10 (2). https:\/\/doi.org\/10.1038\/s41389-021-00302-5 (2021).","DOI":"10.1038\/s41389-021-00302-5"},{"issue":"8","key":"24863_CR56","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3390\/medicina58081135","volume":"58","author":"N Kunac","year":"2022","unstructured":"Kunac, N., Filipovi\u0107, N., Kosti\u0107, S. & Vukojevi\u0107, K. The expression pattern of bcl-2 and Bax in the tumor and stromal cells in colorectal carcinoma. Medicina 58 (8), 1135. https:\/\/doi.org\/10.3390\/medicina58081135 (2022).","journal-title":"Medicina"},{"issue":"1","key":"24863_CR57","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/1878-0261.13077","volume":"16","author":"G Itoh","year":"2021","unstructured":"Itoh, G. et al. Cancer-associated fibroblasts educate normal fibroblasts to facilitate cancer cell spreading and t-cell suppression. Mol. Oncol. 16 (1), 166\u2013187. https:\/\/doi.org\/10.1002\/1878-0261.13077 (2021).","journal-title":"Mol. Oncol."},{"issue":"18","key":"24863_CR58","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1158\/0008-5472.can-22-1427","volume":"82","author":"E Timperi","year":"2022","unstructured":"Timperi, E. et al. Lipid-associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast cancer. Cancer Res. 82 (18), 3291\u20133306. https:\/\/doi.org\/10.1158\/0008-5472.can-22-1427 (2022).","journal-title":"Cancer Res."},{"issue":"1","key":"24863_CR59","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-024-01559-0","volume":"17","author":"B Toledo","year":"2024","unstructured":"Toledo, B. et al. Deciphering the performance of macrophages in tumor microenvironment: a call for precision immunotherapy. J. Hematol. Oncol. 17 (1), 44. https:\/\/doi.org\/10.1186\/s13045-024-01559-0 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"24863_CR60","doi-asserted-by":"publisher","unstructured":"Chen, S. et al. Cancer-associated fibroblast-induced m2-polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor-1 pathway. Int. J. Oncol. 59 (2). https:\/\/doi.org\/10.3892\/ijo.2021.5239 (2021).","DOI":"10.3892\/ijo.2021.5239"},{"issue":"5","key":"24863_CR61","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.3390\/cancers15051620","volume":"15","author":"Y Sheng","year":"2023","unstructured":"Sheng, Y. et al. Cancer-associated fibroblasts exposed to high-dose ionizing radiation promote M2 polarization of macrophages, which induce radiosensitivity in cervical cancer. Cancers 15 (5), 1620. https:\/\/doi.org\/10.3390\/cancers15051620 (2023).","journal-title":"Cancers"},{"key":"24863_CR62","doi-asserted-by":"publisher","first-page":"100960","DOI":"10.1016\/j.drup.2023.100960","volume":"68","author":"R Qi","year":"2023","unstructured":"Qi, R. et al. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting Mirnas. Drug Resist. Updates. 68, 100960. https:\/\/doi.org\/10.1016\/j.drup.2023.100960 (2023).","journal-title":"Drug Resist. Updates"},{"key":"24863_CR63","doi-asserted-by":"publisher","unstructured":"Hauge, A. & Rofstad, E. K. Antifibrotic therapy to normalize the tumor microenvironment. J. Translational Med. 18 (1). https:\/\/doi.org\/10.1186\/s12967-020-02376-y (2020).","DOI":"10.1186\/s12967-020-02376-y"},{"issue":"40","key":"24863_CR64","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1038\/s41388-023-02817-0","volume":"42","author":"G Dong","year":"2023","unstructured":"Dong, G. et al. DDX18 drives tumor immune escape through transcription-activated STAT1 expression in pancreatic cancer. Oncogene 42 (40), 3000\u20133014. https:\/\/doi.org\/10.1038\/s41388-023-02817-0 (2023).","journal-title":"Oncogene"},{"issue":"4","key":"24863_CR65","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/ppo.0000000000000140","volume":"21","author":"CJ Whatcott","year":"2015","unstructured":"Whatcott, C. J., Han, H. & Von Hoff, D. D. Orchestrating the tumor microenvironment to improve survival for patients with pancreatic cancer. Cancer J. 21 (4), 299\u2013306. https:\/\/doi.org\/10.1097\/ppo.0000000000000140 (2015).","journal-title":"Cancer J."},{"issue":"2","key":"24863_CR66","doi-asserted-by":"publisher","first-page":"108","DOI":"10.21147\/j.issn.1000-9604.2023.02.03","volume":"35","author":"M Jiang","year":"2023","unstructured":"Jiang, M., Gu, D., Liu, F., Lin, C. & Tian, L. Transforming cancer cells for long-term living with cancer: an inspiring new approach. Chin. J. Cancer Res. 35 (2), 108\u2013125. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2023.02.03 (2023).","journal-title":"Chin. J. Cancer Res."},{"issue":"4","key":"24863_CR67","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1136\/gutjnl-2018-317570","volume":"68","author":"D Goehrig","year":"2018","unstructured":"Goehrig, D. et al. Stromal protein \u03b2ig-H3 reprogrammes tumor microenvironment in pancreatic cancer. Gut 68 (4), 693\u2013707. https:\/\/doi.org\/10.1136\/gutjnl-2018-317570 (2018).","journal-title":"Gut"},{"key":"24863_CR68","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.semcancer.2024.09.002","volume":"106-107","author":"G Lencioni","year":"2024","unstructured":"Lencioni, G. et al. Unravelling the complexities of resistance mechanism in pancreatic cancer: insights from in vitro and ex-vivo model systems. Sem. Cancer Biol. 106-107, 217\u2013233. 10.1016:j.semcancer.2024.09.002 (2024).","journal-title":"Sem. Cancer Biol."},{"key":"24863_CR69","doi-asserted-by":"publisher","unstructured":"Lan, Y. et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2. Sci. Transl. Med. 10 (424). https:\/\/doi.org\/10.1126\/scitranslmed.aan5488 (2018).","DOI":"10.1126\/scitranslmed.aan5488"},{"issue":"4","key":"24863_CR70","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3390\/cancers14040940","volume":"14","author":"MZ Gungor","year":"2022","unstructured":"Gungor, M. Z., Uysal, M. & Senturk, S. The bright and the dark side of TGF-\u03b2 signaling in hepatocellular carcinoma: Mechanisms, dysregulation, and therapeutic implications. Cancers 14 (4), 940. https:\/\/doi.org\/10.3390\/cancers14040940 (2022).","journal-title":"Cancers"},{"key":"24863_CR71","doi-asserted-by":"publisher","unstructured":"van Pelt, J. et al. Human pancreatic cancer patients with epithelial-to-mesenchymal transition and an aggressive phenotype show a disturbed balance in protein phosphatase type 2A expression and functionality. J. Translational Med. 21 (1). https:\/\/doi.org\/10.1186\/s12967-023-04145-z (2023).","DOI":"10.1186\/s12967-023-04145-z"},{"key":"24863_CR72","doi-asserted-by":"publisher","unstructured":"Li, J., Zhi, X., Sun, Y., Chen, M. & Yao, L. The PDGF family is associated with activated tumor stroma and poor prognosis in ovarian cancer. Disease Markers 2022 Sept 262022:1\u201319. https:\/\/doi.org\/10.1155\/2022\/5940049","DOI":"10.1155\/2022\/5940049"},{"issue":"22","key":"24863_CR73","doi-asserted-by":"publisher","first-page":"5858","DOI":"10.3390\/cancers13225858","volume":"13","author":"L Eibenschutz","year":"2021","unstructured":"Eibenschutz, L. et al. Evaluation of Hedgehog pathway Inhibition on nevoid basal cell carcinoma syndrome fibroblasts and basal cell carcinoma-associated fibroblasts: are vismodegib and sonidegib useful to target cancer-prone fibroblasts? Cancers 13 (22), 5858. https:\/\/doi.org\/10.3390\/cancers13225858 (2021).","journal-title":"Cancers"},{"key":"24863_CR74","doi-asserted-by":"publisher","unstructured":"Sang, Q. et al. Identification of prognostic gene expression signatures based on the tumor microenvironment characterization of gastric cancer. Front. Immunol. 13 https:\/\/doi.org\/10.3389\/fimmu.2022.983632 (2022).","DOI":"10.3389\/fimmu.2022.983632"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24863-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24863-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24863-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T11:43:11Z","timestamp":1765798991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24863-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24863"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-24863-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43750"}}